福安药业(300194) - 2025 Q2 - 季度业绩预告

Performance Forecast The company forecasts a year-over-year decline in its 2025 first-half performance, with net profit attributable to shareholders expected to decrease by 39.95% to 53.81% Performance Forecast Table | Item | Current Period (2025H1) Forecast | Prior Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Profit: 100 million CNY – 130 million CNY | Profit: 216.4775 million CNY | Decrease: 39.95% - 53.81% | | Net Profit Excluding Non-Recurring Gains and Losses | Profit: 91 million CNY – 121 million CNY | Profit: 203.3734 million CNY | Decrease: 40.50% - 55.25% | Explanation of Performance Change The company's performance decline is primarily due to the nationwide implementation of centralized drug procurement policies, which significantly reduced product prices and compressed profit margins - The core reason for the performance decline is the significant reduction in sales prices of the company's main products due to the nationwide implementation of centralized drug procurement (NCDP), leading to lower operating revenue and compressed profit margins[5][6] - Non-recurring gains and losses are estimated to have a positive impact of approximately 9 million CNY on net profit during the current reporting period, primarily from government subsidies[6] Other Explanations and Risk Warnings The company emphasizes that the financial data in this performance forecast are preliminary, unaudited estimates, with final figures to be disclosed in the 2025 semi-annual report, urging investors to be aware of investment risks - The financial data in this performance forecast are preliminary estimates and unaudited by a certified public accountant, thus subject to uncertainty[4][7] - The company advises investors that the specific and accurate financial data will be disclosed in the 2025 semi-annual report, urging caution regarding investment risks[7]